Private Insurers Retrenching on GLP-1 Weight-Loss Coverage

Private employer-sponsored health plans are increasingly restricting coverage for GLP-1 weight-loss medications, reversing a trend that saw adoption rise to approximately 66% of plans in 2026. Data indicates that at least 10% of plans currently covering these drugs intend to discontinue coverage in 2027, with additional firms actively reviewing their benefit designs to mitigate rising pharmacy costs.

This shift is driven by the high net price of GLP-1 therapies, which can exceed $600 per 30-day supply. Given that 40% of the U.S. adult population meets the clinical criteria for obesity, insurers are prioritizing short-term premium stability over the long-term potential for reduced chronic disease expenditures.

The structural misalignment between employer-sponsored insurance and long-term health outcomes remains a primary driver of this volatility. Because employees frequently transition between employers, firms lack the financial incentive to fund preventative treatments that yield savings primarily for future insurers or Medicare. This contraction in coverage threatens to widen health disparities and complicates the integration of high-cost, high-efficacy therapeutics into the broader U.S. healthcare market.